Tekla Capital Management

Tekla Capital Management

Tekla Capital Management

Suggest edits
Follow us
Also headquartered in Boston
Terms of Service Privacy Policy Cookie Statement
Built with ❤︎ by Datalicious ©2022
A daughter company of TNW.
Index.co is not affiliated with Index Ventures.

Overview

News

Investments 13

Portfolio

Portfolio Tracker

Add info
Pulse 2.0

Atreca (BCEL) Stock: Why The Price Is Much Higher Today

Atreca, Inc.
Atreca, Inc.
The
The
MedCity News

Ovid Therapeutics adds to epilepsy drug pipeline with new AstraZeneca alliance

Ovid Therapeutics
Ovid Therapeutics
$215,000,000 Venture capital (Series B)
MedCity News

CRISPR-editing biotech Arbor Bio adds $215M for liver, CNS disease therapies

Arbor Biotechnologies
Arbor Biotechnologies
$80,000,000 Venture capital (Series B)
MedCity News

ReCode Therapeutics gets $80M to deliver on new RNA therapies for the lungs

ReCode Therapeutics
ReCode Therapeutics
Northstack

Oculis raises $57m Series C led by BVCF Management and Hyfinity Investments

Oculis
Oculis
€30,000,000 Venture capital (Series A)
FinSMEs

Priothera Raises €30M in Series A Financing

Priothera
Priothera
SiliconRepublic

Dublin’s Priothera raises €30m to develop leukaemia treatment

Priothera
Priothera
$65,000,000 Venture capital (Series B)
FinSMEs

HotSpot Therapeutics Closes $65M Series B Financing

HotSpot Therapeutics
HotSpot Therapeutics
Xconomy

HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic

HotSpot Therapeutics
HotSpot Therapeutics
$55,000,000 Venture capital (Series C)
Xconomy

Dynacure Adds $55M As RNA-Targeted Muscle Disorder Drug Enters Clinic

Dynacure
Dynacure
$80,000,000 Venture capital (Series A)
Xconomy

With $80M, ReCode Looks to Advance RNA Therapies for Lung Diseases

ReCode Therapeutics
ReCode Therapeutics
Xconomy

With “Inflection Year” Ahead, Ovid Adds Novartis’s Tardio to C-Suite

Ovid Therapeutics
Ovid Therapeutics
Novartis
Novartis
$113,800,000 IPO
PE HUB

Biopharma firm Atreca goes public

Atreca, Inc.
Atreca, Inc.
FinSMEs

Pfizer Acquires Clinical-Stage Biotech Company Therachon, for Up To $810M

Pfizer
Pfizer
Therachon
Therachon
Silicon Canals

Swiss startup Oculis secures €13.8M funding to treat ophthalmic diseases

Oculis
Oculis
$15,711,870 Venture capital (Series B)
FinSMEs , PE HUB

Oculis Raises CHF15.5M in Extension of Series B Financing

Oculis
Oculis
$80,000,000 Venture capital
FinSMEs

Milestone Pharmaceuticals Raises $80M in Equity Funding

Funding Health
Milestone Pharmaceuticals, Inc.
Milestone Pharmaceuticals, Inc.
$125,000,000 Venture capital (Series C)
FinSMEs , PE HUB , MedCity News

Atreca Raises $125M in Series C Funding

Funding
Atreca, Inc.
Atreca, Inc.
$60,000,000 Venture capital (Series B)
FinSMEs

Biotech Company Therachon Raises $60M Mezzanine Financing

Funding Health
Therachon AG
Therachon AG
Therachon
Therachon
$45,000,000 Venture capital (Series A)
PE HUB , FinSMEs

HotSpot Therapeutics scores $45 mln Series A

Data leaks Messaging